	А	В	С
·	Brand-Name Drug	Active ingredient	AG?
1	with Putative AG		(Yes/No)
2	Lowetrol	levohexastatin	
3	Magislim	polydextrastat	
4	Marvacid	trichloroprazole	
5	Painfree	phenylthiocodone	

	А	В	С	D	Е	F
	Brand-Name	Active Ingredient	Dosage	NDA#	Dosage	AG?
	of Drug		Form		Strength	(Yes/No)
	Subject to ¶ 4					
1						
2	Benetan	lactotannate	tablet	17823	40 mg	
3	Benetan	lactotannate	tablet	17823	80 mg	
4	Benetan	lactotannate	tablet	17823	200 mg	
5	Gigatropin DR	methylvitatropin	capsule DR	21777	10 mg	
6	Gigatropin DR	methylvitatropin	capsule DR	21777	20 mg	
7	Gigatropin DR	methylvitatropin	capsule DR	21777	50 mg	
8	Magislim	polydextrastat	tablet	15443	200 mg	
9	Magislim	polydextrastat	tablet	15443	400 mg	
10	Magislim	polydextrastat	tablet	15443	800 mg	
11	Marvacid	trichloroprazole	capsule	18998	15 mg	
12	Marvacid	trichloroprazole	capsule	18998	30 mg	
13	Scherzo XL	dihydrochloramine	tablet XR	27483	60 mg	
14	Scherzo XL	dihydrochloramine	tablet XR	27483	120 mg	
15	Tranquilia XR	isodoxazepam	capsule XR	20490	20 mcg	
16	Tranquilia XR	isodoxazepam	capsule XR	20490	40 mcg	
17	Tranquilia XR	isodoxazepam	capsule XR	20490	80 mcg	
18	Tranquilia XR	isodoxazepam	capsule XR	20490	200 mcg	

	А	В	С	D	Е	F	G	Н	ı	J
	AG Trade	Brand-Name	Active Ingredient	Dosage	NDA#	Dosage	NDA Date	AG - 9 digit	NDC Date	NDC Date of
	Name, if			Form		Strength	of	NDC #	of	Discontinuance, if
	any						Approval	(Labeler	Launch	any
							(for each	Code -		
							strength)	Product		
1								Code)		

	Н	K	L	M	N	0	Р	Q
	AG - 9 digit	AG Labeler/Entity	AG	AG Labeler/	QUESTION 7	STOP!!	QUESTION 10	QUESTION 11
	NDC #	Name	Labeler/Entity	Marketing	Coordinate	FILL IN	Date of first	Settlement
	(Labeler		Relationship to	Entity Address	with	COLUMNS P	announcement	agreement
	Code -		Company	& Phone	marketing	& Q WITH	of AG marketing	related to AG
	Product				entity?	PART III.		marketing?
1	Code)				(Yes/No)			(Yes/No)

	А	В	С	D	E	F	G	Н	ļ	J
	Brand-Name (AG	Active	Dosage	NDA#	Dosage	NDA	9 digit	Labeler/Entity Name	Labeler/Entity	Therapeutic
	version marketed)	Ingredient	Form		Strength	Approval	NDC #		Relationship to	Category
		_				Date (for	(Labeler		Company	
						each	Code -			
						strength)	Product			
1						,	Code)			

	Α	K	L	М	N	0	Р	Q	R
	Brand-Name (AG	Pharmacological	14-Digit Generic	Date of	Generic	Name of ANDA-	Name of ANDA	Name of	Enter columns
	version marketed)	Class	Product Identifier	first	entry via 180	Generic	Generic	ANDA-	for additional
				ANDA-	day	Company #1	Company #2	Generic	companies
				generic	exclusivity?	During	During	Company #3	here▶▶
				entry (or	(Yes/No)	Exclusivity	Exclusivity	During	
1				"none")		•		Exclusivity	

	А	В	С	D	Е	F	G	Н	
1	Brand-Name (¶ IV- no AG marketed)	Active Ingredient	Dosage Form	NDA #	Dosage Strength	NDA Approval Date (for each strength)	9 digit NDC # (Labeler Code - Product Code)	Labeler/Entity Name	Labeler/Entity Relationship to Company

	Α	J	K	L	М	N	0	Р	Q	R	S
	Brand-Name (¶ IV-	Therapeutic	Pharma-	14-Digit	Date of	Generic	Name of	Name of	Name of	Enter	Question 14
	no AG marketed)	Category	cological	Generic	first	entry via 180	ANDA-	ANDA-	ANDA-	columns for	AG <u>NOT</u>
			Class	Product	ANDA-	day	Generic	Generic	Generic	additional	Marketed Per
				Identifier	generic	exclusivity?	Company #1	Company	Company	companies	Settlement
					entry (or	(Yes/No)	During	#2 During	#3 During	here▶▶	Agreement
					"none")		Exclusivity	Exclusivity	Exclusivity		(Yes/NO)
1					•			-			